Share on

In this video, IMF Chairman Brian G.M. Durie moderates a discussion about the clinical trials regarding Frontline Therapies with Dr. Joseph Mikhael (IMF Chief Medical Officer) and Dr. Philippe Moreau (University of Nantes - Nantes, France). Trials discussed included:

  • CASSIOPEIA, which compares daratumumab plus Velcade, Thalidomide, and dexamethasone (VTd) to VTd-alone
  • MAIA, which compares daratumumab plus lenalidomide and dexamethasone to lenalidomide and dexamethasone-alone
  • A study of subcutaneous daratumumab
  • FORTE trial: Kyprolis, Revlimid and dexamethasone with or without a transplant

This video is the second in a five-part series that focuses on making sense of multiple myeloma treatment based upon the newly obtained input from the American Society of Clinical Oncology (ASCO) and the International Myeloma Working Group 2019 Summit.

Download Slides

Topics Covered:


Thank you to our sponsors:
Takeda Oncology

 

Previous Post
Smoldering Multiple Myeloma
Next Post
Maintenance

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.